Fluorine F 18 Fluorthanatrace for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Breast CancerFluorine F 18 Fluorthanatrace - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new imaging agent, [18F]FluorThanatrace, to see if it can improve imaging techniques in patients with breast cancer.

Eligible Conditions
  • Breast Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
Correlation of [18F]FluorThanatrace (FTT) uptake with PARP expression

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment ([18F]FTT PET/CT)
1 of 1

Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: Fluorine F 18 Fluorthanatrace · No Placebo Group · Phase 2

Treatment ([18F]FTT PET/CT)Experimental Group · 3 Interventions: Positron Emission Tomography, Computed Tomography, Fluorine F 18 Fluorthanatrace · Intervention Types: Procedure, Procedure, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2008
Completed Phase 2
~2820
Computed Tomography
2017
Completed Phase 2
~3410

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,802 Previous Clinical Trials
1,788,867 Total Patients Enrolled
141 Trials studying Breast Cancer
30,200 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,070 Previous Clinical Trials
41,129,078 Total Patients Enrolled
924 Trials studying Breast Cancer
1,535,779 Patients Enrolled for Breast Cancer
Trevarx Biomedical, IncUNKNOWN
Lilie L LiliePrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to participate in the study.
You are informed of the investigational nature of this study and provide written informed consent, in accordance with institutional and federal guidelines prior to study-specific procedures.